<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091777</url>
  </required_header>
  <id_info>
    <org_study_id>GDC-229-002</org_study_id>
    <nct_id>NCT03091777</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gage Development Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gage Development Company, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to compare the safety and efficacy of GDC-229 (test drug)
      against the currently marketed reference drug (metronidazole 0.75% vaginal gel) and to
      establish that these two drugs work better than placebo in subjects with BV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">November 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>Day 21-30</time_frame>
    <description>Resolution of clinical signs and symptoms</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">871</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC-229 gel applied vaginally as directed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GDC-229 Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-229</intervention_name>
    <description>GDC-229 is a vaginal gel.</description>
    <arm_group_label>Test Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Vaginal Gel 0.75%</intervention_name>
    <description>Metronidazole Vaginal Gel 0.75% is an FDA-approved drug</description>
    <arm_group_label>Reference Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive arm of the study</description>
    <arm_group_label>Vehicle Placebo Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-pregnant female aged ≥ 18 years who is in good general health

          2. Diagnosis of BV

          3. Willing to refrain from using any intravaginal product (e.g., spermicide, tampon,
             douche, feminine deodorant spray, diaphragm, vaginal ring birth control, or condom
             with spermicide or insertion into the vagina of any drug or non-drug product during
             treatment), other than study treatment for the duration of the trial

          4. Subjects of childbearing potential who have a negative urine pregnancy test at the
             Entry Visit (Visit 1) and agree to use an acceptable form of birth control throughout
             the study

          5. Able to understand and willing to sign the informed consent form (ICF) and able to
             comply with the requirements of the protocol

        Exclusion Criteria:

          1. History of alcohol or substance abuse

          2. Experienced a clinically significant medical event within 90 days

          3. Abnormal pap or high risk human papillomavirus (HPV)

          4. History or presence of clinically significant central nervous system (CNS),
             cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine,
             immunologic, gynecologic, dermatologic, neurologic, oncologic, or psychiatric disease

          5. Pregnant, lactating, or planning to become pregnant or breastfeed during the study
             period

          6. Primary or secondary immunodeficiency

          7. Evidence of any vulvovaginitis at screening other than BV

          8. History of hypersensitivity or allergy to metronidazole, parabens, other
             nitroimidazole derivatives, or other ingredients of the GDC 229 (metronidazole 0.75%
             vaginal gel), metronidazole 0.75% vaginal gel (Oceanside Pharmaceuticals), or vehicle
             gel

          9. Participating in another clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Non-pregnant female aged ≥ 18 years who is in good general health</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <results_first_submitted>August 1, 2019</results_first_submitted>
  <results_first_submitted_qc>September 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2019</results_first_posted>
  <disposition_first_submitted>February 25, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>February 25, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 28, 2019</disposition_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bacterial vaginosis</keyword>
  <keyword>vaginal infection</keyword>
  <keyword>BV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03091777/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03091777/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: March 2017 to November 2017
The location of clinical sites included women's health clinics and clinical research centers</recruitment_details>
      <pre_assignment_details>All subjects who met the entry criteria were randomized and enrolled into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Test Drug</title>
          <description>GDC-229 gel applied vaginally as directed.
GDC-229: GDC-229 is a vaginal gel.</description>
        </group>
        <group group_id="P2">
          <title>Reference Drug</title>
          <description>Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
Metronidazole Vaginal Gel 0.75%: Metronidazole Vaginal Gel 0.75% is an FDA-approved drug</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Placebo Gel</title>
          <description>GDC-229 Vehicle
Placebo: Inactive arm of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="288"/>
                <participants group_id="P3" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="255"/>
                <participants group_id="P3" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Laboratory Value</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Drug</title>
          <description>GDC-229 gel applied vaginally as directed.
GDC-229: GDC-229 is a vaginal gel.</description>
        </group>
        <group group_id="B2">
          <title>Reference Drug</title>
          <description>Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
Metronidazole Vaginal Gel 0.75%: Metronidazole Vaginal Gel 0.75% is an FDA-approved drug</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Placebo Gel</title>
          <description>GDC-229 Vehicle
Placebo: Inactive arm of the study</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="287"/>
            <count group_id="B2" value="285"/>
            <count group_id="B3" value="292"/>
            <count group_id="B4" value="864"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="8.56"/>
                    <measurement group_id="B2" value="33.2" spread="9.61"/>
                    <measurement group_id="B3" value="33.5" spread="9.77"/>
                    <measurement group_id="B4" value="33.3" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="292"/>
                    <measurement group_id="B4" value="864"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="235"/>
                    <measurement group_id="B4" value="701"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="483"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="351"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="292"/>
                    <measurement group_id="B4" value="864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cure</title>
        <description>Resolution of clinical signs and symptoms</description>
        <time_frame>Day 21-30</time_frame>
        <population>Modified Intent-to-Treat (mITT) population: All randomized subjects who received study treatment and returned for at least one post-baseline visit, but excluding those who demonstrate a positive test result for other concomitant vaginal or cervical infections at baseline (e.g. C. trachomatis, N. gonorrhoeae) or who have a baseline Nugent score&lt;4.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Drug</title>
            <description>GDC-229 gel applied vaginally as directed.
GDC-229: GDC-229 is a vaginal gel.</description>
          </group>
          <group group_id="O2">
            <title>Reference Drug</title>
            <description>Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
Metronidazole Vaginal Gel 0.75%: Metronidazole Vaginal Gel 0.75% is an FDA-approved drug</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Placebo Gel</title>
            <description>GDC-229 Vehicle
Placebo: Inactive arm of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure</title>
          <description>Resolution of clinical signs and symptoms</description>
          <population>Modified Intent-to-Treat (mITT) population: All randomized subjects who received study treatment and returned for at least one post-baseline visit, but excluding those who demonstrate a positive test result for other concomitant vaginal or cervical infections at baseline (e.g. C. trachomatis, N. gonorrhoeae) or who have a baseline Nugent score&lt;4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="129"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Drug</title>
          <description>GDC-229 gel applied vaginally as directed.
GDC-229: GDC-229 is a vaginal gel.</description>
        </group>
        <group group_id="E2">
          <title>Reference Drug</title>
          <description>Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
Metronidazole Vaginal Gel 0.75%: Metronidazole Vaginal Gel 0.75% is an FDA-approved drug</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Placebo Gel</title>
          <description>GDC-229 Vehicle
Placebo: Inactive arm of the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <description>Exacerbation Of Supraventricular Tachycardia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle Cell Anaemia</sub_title>
                <description>Worsening Sickle Cell Anemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <description>Enterocolic Intussusception</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <description>Acute Cholecystitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="287"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="285"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gage Development Company</name_or_title>
      <organization>Gage Development Company</organization>
      <phone>1-847-999-0600</phone>
      <email>clinicalinfo@capstonedevservices.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

